Howard Noveck, MD
Interventional Cardiology · Edison, NJNPI 1871543389
Payments from drug & device makers
Across 443 payments — averaging $31.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- AstraZeneca$3K
- Cvrx, Inc.$1K
- Boston Scientific$866
- Johnson & Johnson$781
- Novartis$597
- plus $4K from 34 others
What the payments were for
- Travel & lodging$1,87417%
- Food & beverage$9,08383%
- Education$420%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 34 | $3,288 |
| AstraZeneca | 15 | $3,092 |
| Cvrx, Inc. | 12 | $1,211 |
| Boston Scientific | 18 | $866 |
| Johnson & Johnson(2 entities) | 62 | $781 |
| Novartis | 64 | $597 |
| Boehringer Ingelheim | 26 | $391 |
| Novo Nordisk | 31 | $380 |
| Heartflow, Inc. | 11 | $346 |
| E.r. Squibb & Sons, L.L.C. | 31 | $334 |
| Amgen | 18 | $273 |
| Impulse Dynamics (USA) Inc. | 4 | $265 |
| Pfizer | 22 | $220 |
| Merck | 13 | $199 |
| Bayer | 9 | $151 |
| Sanofi-aventis U.S. LLC | 9 | $136 |
| Esperion Therapeutics, Inc. | 8 | $135 |
| Abiomed | 4 | $120 |
| Medtronic | 3 | $99 |
| Atricure, Inc. | 3 | $98 |
| Shockwave Medical, Inc | 1 | $97 |
| Bridgebio Pharma, Inc. | 5 | $85 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $76 |
| Amarin Pharma, Inc. | 5 | $71 |
| United Therapeutics Corporation | 4 | $68 |
| Scpharmaceuticals Inc. | 3 | $53 |
| Gilead | 4 | $50 |
| Corcept Therapeutics | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Biosense Webster, Inc. | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 2 | $29 |
| Acarix USA Inc. | 2 | $27 |
| Lilly USA, LLC | 2 | $24 |
| Edwards Lifesciences | 1 | $22 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Exact Sciences | 1 | $16 |
| Terumo Medical Corporation | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCLOSE PROGLIDE$2,069
- Barostim Neo System$987
- OPTIMIZER$228
- MitraClip$150
- WATCHMAN FLX$143
- HeartMate Touch$133
- COROFLOW$130
- FFRct$124
- FARXIGA$118
- OPTIMIZER SMART SYSTEM$112
How this compares
$13,775 in reported general payments places this provider in the 60th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 263 | $279,635 |
| EntrestoSacubitril/Valsartan | 207 | $229,908 |
| JardianceEmpagliflozin | 169 | $205,835 |
| XareltoRivaroxaban | 143 | $164,913 |
| OzempicSemaglutide | 75 | $128,085 |
| Repatha SureclickEvolocumab | 94 | $107,078 |
| FarxigaDapagliflozin Propanediol | 67 | $83,997 |
| MultaqDronedarone Hcl | 55 | $77,941 |
| BrilintaTicagrelor | 59 | $56,987 |
| TrulicityDulaglutide | 41 | $56,931 |
| Tadalafil | 11 | $53,731 |
| Ambrisentan | 19 | $53,455 |
| RybelsusSemaglutide | 28 | $35,465 |
| VascepaIcosapent Ethyl | 52 | $23,572 |
| JanuviaSitagliptin Phosphate | 16 | $15,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $220 | $279,635263 claims |
| NovartisEntresto | $597 | $229,908207 claims |
| Boehringer IngelheimJardiance | $391 | $205,835169 claims |
| Johnson & JohnsonXarelto | $781 | $164,913143 claims |
| Novo NordiskOzempic, Rybelsus | $380 | $163,551103 claims |
| AstraZenecaFarxiga, Brilinta | $3,092 | $140,984126 claims |
| Sanofi-aventis U.S. LLCMultaq | $136 | $77,94155 claims |
| Lilly USA, LLCTrulicity | $24 | $56,93141 claims |
| MerckJanuvia | $199 | $15,11116 claims |
| Esperion Therapeutics, Inc.Nexlizet | $135 | $12,48612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Edison
- Ossama ElsaidEdison$34K
- Dinesh SingalSomerset$1.4M
- Ankitkumar PatelGlen Ridge$717K
- Matthew SayboltEatontown$671K
- Jaffar RazaSecaucus$537K
- Kintur SanghviBordentown$467K
- Ziad AbbudOcean$361K
- Ramin HastingsHasbrouck Heights$355K
- Ryan KapleHackensack$280K
- Haroon FarazTeaneck$269K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.